Capital Increase in Genmab as a Result of Employee Warrant Exercise

How will the capital increase from the employee warrant exercise affect the share price in the short term? Will the increase in shares affect the company’s ability to meet debt covenants or other financial covenants? What is the degree of dilution for existing shareholders and how does it compare to previous capital raises? What is the total amount of new capital being raised and at what price per share? How does the exercise of employee warrants impact the company’s cash flow and balance sheet? Are there any lock‑up periods or restrictions on the newly issued shares? How does this capital raise compare to similar transactions by peers in the biotech/pharma sector? What are the intended uses of the newly raised capital and will they fund upcoming R&D projects or acquisitions? How might this capital increase affect the company’s valuation multiples (e.g., P/E, EV/EBITDA) and analyst rating? What are the tax implications for employees exercising the warrants and for the company?